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The indications of immune checkpoint inhibitors (ICIs) are set to rise further with
the approval of newer agents like tremelimumab and atezolimumab for use in
patients with advanced stage mesothelioma and urothelial carcinoma respectively.
More frequent use of ICIs has improved our understanding of their unique side
effects, which are known as immune-related adverse events (irAEs). The spectrum of
irAEs has expanded beyond more common manifestations such as dermatological,
gastrointestinal and endocrine effects to rarer presentations involving nervous,
hematopoietic and urinary systems. There are new safety data accumulating on ICIs
in patients with previously diagnosed autoimmune conditions. It is challenging for
clinicians to continuously update their working knowledge to diagnose and manage
these events successfully. If diagnosed timely, the majority of events are completely
reversible, and temporary immunosuppression with glucocorticoids, infliximab or other
agents is warranted only in the most severe grade illnesses. The same principles of
management will possibly apply as newer anti- cytotoxic T lymphocytes-associated
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1/PD-L1) antibodies
are introduced. The current focus of research is for prophylaxis and for biomarkers
to predict the onset of these toxicities. In this review we summarize the irAEs of ICIs
and emphasize their growing spectrum and their management algorithms, to update
oncology practitioners.
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INTRODUCTION
Recent advances in cancer immunotherapy are notable for the introduction of a novel class of
drugs known as immune checkpoint inhibitors (ICIs). These agents inhibit negative regulatory
components of the immune response, such as the cytotoxic T lymphocytes-associated antigen 4
(CTLA-4) and the programmed cell death protein-1 and its ligand (PD-1/PD-L1), which lead to
enhanced T cell action against the cancer cells (Hodi et al., 2010). Ipilimumab is an anti- CTLA-4
antibody and was the first agent to receive food and drug administration (FDA) approval for use
Kumar et al. Management of irAEs Secondary to ICIs
against advanced-stage melanoma1. Since then anti- CTLA-4
antibody tremelimumab, anti-PD-1 antibodies pembrolizumab
and nivolumab and PD-L1 antibodies, atezolizumab and
durvalumab, have shown beneficial effects in several cancers
(Wolchok et al., 2010; Topalian et al., 2012, 2014; Ribas et al.,
2013b; Larkin et al., 2015; Robert et al., 2015a; Postow et al.,
2015; Fehrenbacher et al., 2016; Ferris et al., 2016; Massard et al.,
2016; Reck et al., 2016; Rittmeyer et al., 2017) (Table 1). In
contrast to conventional chemotherapy, boosting the immune
system leads to a unique constellation of inflammatory toxicities
known as immune-related adverse events (irAEs) that may
warrant the discontinuation of therapy and/or the administration
of immunosuppressive agents (Gangadhar and Vonderheide,
2014; Cousin and Italiano, 2016). The use of these agents is
set to increase due to their dramatic impact on survival in a
variety of advanced-stage cancers (Horvat et al., 2015). Thus,
it is imperative for personnel involved in the care of oncology
patients to be well versed with the heterogeneous presentations of
irAEs in terms of recognition and management. Here, we review
the current literature on appropriate steps in patient evaluation
for the prompt diagnosis of irAEs and describe strategies for
optimizing patient outcome with suitable treatment.
Incidence
The incidence of any grade irAEs is reported to range from 15
to 90% (Hodi et al., 2010; Eggermont et al., 2016; Ferris et al.,
2016) in single agent trials. The rate of severe irAEs requiring
immunosuppression and withdrawal of immunotherapy is
estimated to be 0.5–13% (Hodi et al., 2010; Wolchok et al.,
2010; Topalian et al., 2012, 2014; Ribas et al., 2013b; Larkin
et al., 2015; Postow et al., 2015; Robert et al., 2015a; Ferris
et al., 2016; Table S1)1. The high incidence reported in a recent
study was attributed to subjectivity in toxicity evaluations among
investigators and the accumulation of experience leading to
early diagnosis (Horvat et al., 2015). The risk of severe grade
adverse events increased from 7 to 25% with an increase in
the dose of ipilimumab from 3 mg/kg to 10 mg/kg9. This was
mostly due to increase in the episodes of diarrhea. However, this
pattern was not observed when nivolumab dosing was increased
from 0.3 mg/kg to 10 mg/kg10. Severe grade toxicities with
pembrolizumab were also similar at doses of 10 mg/kg every 2 or
3 weeks and its FDA-approved dosage of 2 mg/kg every 3 weeks
(Herbst et al., 2016). Thus, it may be argued that toxicities due
to anti-CTLA-4 antibodies are dose dependent whereas toxicities
with anti-PD-1/anti-PDL-1 antibodies are independent of doses.
Ipilimumab, a CTLA-4 inhibitor is associated with higher rates of
gastrointestinal (GI) toxicities, pruritus, rash, and hypophysitis
whereas use of PD-1/PD-L1 antagonists is associated with higher
risk of vitiligo, dysthyroidism, hepatotoxicity, and pneumonitis
(Hamid et al., 2013; Weber J. S. et al., 2013; Brahmer et al., 2015;
Eggermont et al., 2015, 2016; Herbst et al., 2016; Table 1 and
Table S1). The data on toxicities from newer agents continue
to accumulate. The irAEs in select clinical trials have been
summarized in Table S1.
1Drugs@FDA: FDA Approved Drug Products. Available online at www.Accessdata.
fda.gov/scripts/cder/drugsatfda/index.cf.
Timing
The majority of toxicities appear temporally, with skin
manifestations the earliest to appear at 2–3 weeks after the
1st dose of ipilimumab. Immune-mediated colitis and hepatitis
appear approximately 5–10 and 12–16 weeks after the 2nd
and 3rd dose, respectively. Endocrine dysfunctions present
from the 9th week onwards following the 4th dose (Hodi et al.,
2010; Ryder et al., 2014). Immune-mediated pneumonitis is
seen 8–14 weeks after treatment initiation (Hodi et al., 2010).
Immune-mediated nephritis appears much later, after 14–42
weeks on immunotherapy (Izzedine et al., 2014). However,
similar temporal association of the appearance of irAEs has not
been described for PD-1/PDL-1 antagonists (Naidoo et al., 2015).
General Principles of Management
Current guidelines are formulated by manufacturers in
collaboration with the FDA and are based on the experience
from clinical trials examining the efficacy of ICIs and expert
consensus. The guidelines are incorporated in the packaging
inserts of these agents2,3,4,5. Although anti-PD-1/ anti-PDL-1
antibodies may be less toxic than anti-CTLA-4 antibodies, the
approach to managing irAEs due to these agents is similar, with
slight variations (Postow and Wolchok, 2016). The severity of
adverse events is graded using Common Terminology Criteria
for Adverse Events (CTCAE) on a scale from 1 to 5 (1 = mild,
2 = moderate, 3 = severe, 4 = life threatening, and 5 = death
related to toxicity) (National Cancer Institute, 2009). However,
the grading of irAEs may be challenging, due to arbitrary
distinctions between grade 2 and 3 toxicities, such as the number
of stools in a day, may be affected by recall bias. Thus, this system
of grading may not be entirely suitable to grade ICIs toxicities
(Horvat et al., 2015). Therefore, it is prudent to use clinical
judgment rather than strictly adhering to the guidelines. We
have outlined several general principles that should be followed
irrespective of affected organs2,3,4,5.
â The ICIs are interrupted in moderate (grade 2) irAEs and
are resumed when symptoms and/or lab values decrease below
grade 1. Glucocorticoids (prednisone 0.5–1 mg/kg/day or
equivalent) should be started if symptoms persist beyond 1
week.
â For grade 3/4 toxicities, high doses of glucocorticoids
(prednisone 1–2 mg/kg/day or equivalent) should be given.
The glucocorticoids should be tapered gradually when
symptoms subside to grade 1 or less. The eligible patients
(those on prednisone 20mg or equivalent doses for at least
4 weeks) should also receive appropriate prophylaxis against
Pneumocystis jirovecii as per the established guidelines6.
2http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf
3Yervoy R© [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2016.
Available online: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=
2265ef30-253e-11df-8a39-0800200c9a66
4Keytruda R© [package insert]. Whitehouse Station, NJ: Merck, and Co.,
Inc., 2016. Available online: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=9333c79b-d487-4538-a9f0-71b91a02b287
5Opdivo R© [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2016.
Available online: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=
f570b9c4-6846-4de2-abfa-4d0a4ae4e394
6http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.
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â Alternative immunosuppressive agents should be considered
(infliximab 5 mg/kg; mycophenolate mofetil in hepatitis)
if symptoms continue beyond 3 days on intravenous
glucocorticoids. Infliximab 5 mg/kg should be repeated after
2 weeks for persistent symptoms.
â For grade 4 toxicities, ICIs should be stopped permanently
except in endocrinopathies controlled on hormone
replacement. Therapy can be resumed in selected patients
with grade 3 toxicities, as discussed in the organ-specific
toxicities section.
ICIs should also be stopped permanently in the following
circumstances2,3,4,5:
â Grade 2 reactions lasting for 6 weeks or longer. However,
anti- PD-1/anti-PD-L1 antibodies can be continued in
endocrinopathies controlled with hormone replacement.
â Inability to reduce glucocorticoids dose to 7.5mg prednisone
or equivalent per day for patients treated with anti-CTLA-
4 antibodies and less than 10mg /day within 12 weeks for
anti-PD-1 antibodies.
â Grade 2–4 ocular reactions not improving to grade 1 within
2 weeks after treatment with topical immunosuppression or
requiring systemic treatment.
Impact of irAEs and Immunosuppression
on Efficacy
The immunosuppressive agents used to treat irAEs do not appear
to affect the response to further immunotherapy (Attia et al.,
2005). In contrast to previous studies, a recent retrospective
analysis reported similar overall survival in patients who received
immunosuppression (Horvat et al., 2015). The association
between irAEs and the efficacy of ICIs is also controversial (Attia
et al., 2005).
Biomarkers
Biomarkers which could predict the development of toxicities
have been described in the patients on ipilimumab. An
increase from baseline in eosinophils and interleukin 17 (IL-
17) after treatment has been shown to be associated with
irAEs (Callahan et al., 2011; Schindler et al., 2014). On
gene profiling, two markers of neutrophil activation, CD177
and CEACAM1 also show promise as biomarkers of ICIs
toxicity. These genes are expressed increasingly in the blood of
patients, who developed GI toxicity after treatment with anti-
CTLA-4 antibodies (Shahabi et al., 2013). Higher risk of GI
toxicity was also seen in patients who exhibited evidence of
inflammation on colon biopsies like infiltration of lamina propria
by neutrophils and presence of cryptic abscesses, erosions and
gland destruction prior to the initiation of treatment (Berman
et al., 2010). However, routine testing of these biomarkers is not
recommended yet.
Organ-Specific Immune Related Adverse
Events
Systemic Adverse Events
Fatigue is the most common symptom reported by up to 40%
of patients after treatment with anti-CTLA-4 antibodies (Weber,
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2009; Hodi et al., 2010; Ibrahim et al., 2011; Tarhini et al.,
2012; Calabro et al., 2015; Larkin et al., 2015; Kindler et al.,
2016) and 16–24% of patients treated with anti-PD-1/anti-PD-
L1 antibodies in single-agent trials (Borghaei et al., 2015; Garon
et al., 2015; Rizvi et al., 2015; Robert et al., 2015a,b; Nanda
et al., 2016; Reck et al., 2016; Rosenberg et al., 2016; Seiwert
et al., 2016). This fatigue is usually mild, and the presence
of severe fatigue should trigger an assessment for underlying
disorders such as endocrinopathies2,3,4,5. Infusion reactions,
including fever and chills, are more common with CTLA-4
inhibitors accounting for AEs in phase III studies (Momtaz
et al., 2015). They are rarely high grade and may be managed
supportively with antipyretics and antihistamines (Villadolid and
Amin, 2015).
Dermatological
Skin manifestations, such as rash/pruritus and mucositis, are the
most common irAEs associated with ICIs. Approximately 47–
68% of patients treated with anti-CTLA-4 antibodies and 30–
40% patients treated with anti-PD-1/anti-PD-L1 antibodies suffer
skin toxicities of any grade (Weber, 2009; Hodi et al., 2010;
Wolchok et al., 2010; Ibrahim et al., 2011; Tarhini et al., 2012;
Topalian et al., 2012; Ribas et al., 2013b; Topalian et al., 2014;
Postow et al., 2015; Borghaei et al., 2015; Calabro et al., 2015;
Garon et al., 2015; Larkin et al., 2015; Rizvi et al., 2015; Robert
et al., 2015a,b; Ferris et al., 2016; Kindler et al., 2016; Nanda
et al., 2016; Rosenberg et al., 2016; Seiwert et al., 2016)1. The
characteristic rash is faintly erythematous and maculopapular,
involves the trunk and extremities and may be pruritic (Jaber
et al., 2006). Vitiligo is also common and has delayed appearance
after several months of treatment with ICIs (Weber, 2012).
Histological analysis shows perivascular lymphocytic infiltration
deep in the dermis with CD4+ and CD8+ T cells in close
proximity with melanocytes (Jaber et al., 2006). The treatment of
symptomatic cases with topical glucocorticoids (betamethasone
0.1% cream) or urea-containing creams and oral antipruritic
agents (diphenhydramine, hydroxyzine, GABA agonists, or NK-
1 receptor antagonists) for troublesome pruritus is usually
sufficient (Weber, 2012; Horvat et al., 2015). The majority of
skin eruptions are mild, and immunotherapy can be continued
in most patients (Weber, 2012). Severe (Grade 3 defined as
papules and/or rash covering >30% BSA) cases should be
treated with oral glucocorticoids for 3–4 weeks, with temporary
discontinuation of ICIs (Table 2). Permanent discontinuation
should be considered in more severe cases, such as Stevens–
Johnson syndrome, but fortunately severe irAEs are rare. Patients
who fail to respond to steroids or have bullae formation merit
dermatologic evaluation and skin biopsy. Oral mucositis and
dryness are seen more frequently with anti-PD-1/anti-PD-L1
antibodies than with anti-CTLA-4 antibodies (Weber, 2009;
Ibrahim et al., 2011; Tarhini et al., 2012; Borghaei et al.,
2015; Calabro et al., 2015; Garon et al., 2015; Rizvi et al.,
2015; Robert et al., 2015b; Kindler et al., 2016; Nanda et al.,
2016; Rosenberg et al., 2016; Seiwert et al., 2016). Topical
glucocorticoids and lidocaine are used for treatment. These
lesions may mimic oral candidiasis, which should be ruled
out2,3,4,5.
Gastrointestinal
Diarrhea and colitis are more common with anti-CTLA-4
antibodies and are reported in 30–40% of patients treated with
ipilimumab (Hodi et al., 2010). Grade 3/4 diarrhea is seen in up
to 10% of patients on ipilimumab therapy and 1–2% of cases
treated with anti-PD-1/anti-PD-L1 antibodies alone (Weber,
2009; Ibrahim et al., 2011; Tarhini et al., 2012; Borghaei et al.,
2015; Calabro et al., 2015; Garon et al., 2015; Rizvi et al., 2015;
Robert et al., 2015b; Kindler et al., 2016; Nanda et al., 2016;
Rosenberg et al., 2016; Seiwert et al., 2016). Enteritis without
colonic involvement leading to small bowel obstruction can also
be seen. Colitis predominantly affects the descending colon (Oble
et al., 2008). Patients with significant diarrhea/colitis during
ipilimumab treatment have subsequently been treated with anti-
PD-1/anti-PD-L1 antibodies without developing diarrhea/colitis
(Naidoo et al., 2015).
Grade 1 gastrointestinal events are classified as increase in
stool frequency of less than 4 per day or mildly increased
ostomy output from baseline (Table 2). Mild cases should
be managed symptomatically with loperamide, oral hydration
and electrolyte replacement (Weber et al., 2015). Other
etiologies such as infection with Clostridium difficile or other
viral/bacterial pathogens should be excluded (Du-Thanh et al.,
2015). The American Dietary Association colitis diet may
also be beneficial2,3,4,5. Treatment with glucocorticoids is
indicated for worsening of symptoms or persistence beyond
3 days. Grade 2 severity events are 4–6 stools per day
over baseline or a moderate increase in ostomy output.
These events are managed by oral diphenoxylate, atropine
or budesonide, in addition to symptomatic treatment. It is
important to rule out colitis by performing a colonoscopy
in persistent grade 2 or grade 1 diarrhea with hematochezia.
Grade 2 diarrhea with bleeding/ulceration should be treated
with oral glucocorticoids and interruption of immunotherapy.
Grade 3 events include diarrhea with 7 or more stools
per day above the baseline, incontinence or severe increase
in ostomy limiting self-care activities. Grade 4 is any life-
threatening complication, such as bowel perforation, requiring
acute intervention. Grade 3 and 4 events should be treated
with intravenous glucocorticoids in addition to symptomatic
treatment2,3,4,5.
The symptomatic improvement should be noted in 48–
72 h. Hospitalization is warranted for parenteral glucocorticoids
with fluid and electrolyte management in cases refractory to
oral glucocorticoids (Weber, 2012; Weber et al., 2015). If
the symptoms fail to resolve after 3 days on intravenous
glucocorticoids (methylprednisolone 2 mg/kg or equivalent),
then infliximab should be given at a dose of 5 mg/kg every 2
weeks2,3,4,5. The use of infliximab for this indication is based
on its efficacy in Crohn’s disease (Minor et al., 2009). However,
the recommendations are not clear for non-resolving symptoms
on infliximab therapy, and prolonged courses of glucocorticoids
are preferred. These patients should be cautiously observed
for GI complications, including perforation and obstruction.
The prompt intervention is mandatory because colitis related
mortality has been attributed to delayed reporting and lack of
ICI withholding (Naidoo et al., 2015). The efficacy of matrix
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TABLE 2 | Summary of management of selected immune related adverse events (irAEs).
S.N. Organ system Manifestations Management
1. Dermatological
q Most common manifestation and earliest to
occur.
q Seen in 2–3 weeks after initiation of treatment
with ipilimumab.
q Commonly seen after the first dose.
q Manifests as maculopapular rash, erythema,
pruritus, dry skin, alopecia or hypertrichosis,
lichenoid keratosis and vitiligo.
More common with CTLA-4 inhibitors. Seen in
up to 47–68% patient on anti-CTLA-4 therapy
and 30–40% patients on anti-PD-1/anti-PD-L1
therapy. Mucositis and vitiligo are more common
in patients receiving anti-PD-1/anti-PD-L1
agents
Immune mediated dermatitis
Grade* 1: Rash affecting <10% BSA.
Mostly Asymptomatic
q Diagnosis: Mucocutaneous examination.
q Treatment: Continue immunotherapy
Symptomatic treatment with oral antihistaminic
drugs.
Topical steroids.
Grade 2: Rash affecting 10–30% BSA. q Diagnosis: clinical examination and lab testing
for LFTs, KFTs, serum tryptase and IgE levels
q Treatment: Withhold immunotherapy**.
Resume after toxicity improves to grade 1 or
lower@.
Symptomatic treatment with oral antihistaminic
drugs.
Oral Prednisone 0.5–1mg/kg/day or equivalent
taper over 4 weeks if symptoms resolve.
Grade 3/4: Rash covering >30% BSA.
Severe life threatening symptoms
Generalized exfoliative/ulcerated rash
q Diagnosis: As in grade 2 plus skin biopsy
q Treatment: Withhold immunotherapy.
Consult Dermatologist.
Resume after toxicity improves to grade 1 or
lower.
Symptomatic treatment with oral antihistaminic
drugs.
Oral Prednisone# 1–2mg/kg/day or equivalent
taper over 4 weeks if symptoms resolve.
Consider alternative immunosuppressive agent
(Cyclophosphamide, Mycophenolate mofetil, or
Infliximab) if symptoms don’t improve after 48 h.
2. Gastrointestinal
q Seen 5–10 weeks later typically after 2nd dose
of ipilimumab.
q Manifests as increase in stool frequency, diarrhea
or constipation, blood or mucus in stool,
abdominal pain/cramping, nausea and vomiting.
q More common with anti-CTLA-4 therapy
(30–40%). Grade 3 and 4 toxicities 1n 10%
patients against 1–2% on anti-PD-1/anti-PD-L1
therapy
Immune mediated colitis
Grade 1: =4 stools/day over baseline. Mild
abdominal symptoms
q Diagnosis: stool microscopic examination for
ova, parasites and stool culture. Stool antigen for
c. difficile if suspected clinically. Lab testing for
LFTs and KFTs.
q Treatment: Continue immunotherapy.
Symptomatic treatment and monitor for fluid
electrolytes balance. American diet Association
(ADA) colitis diet, loperamide or atropine sulfate.
Budesonide can be tried if symptoms persist
beyond 2–3 days.
Grade 2: Moderate new symptoms.
4–6 stools/day over baseline.
q Diagnosis: As above in grade 1. Evaluate for
other causes like progression of primary disease.
Colonoscopymay be beneficial in selected cases.
q Treatment: withhold immunotherapy. If
symptoms improve to grade I resume
immunotherapy.
Symptomatic treatment.
If symptoms are persistent beyond 5–7 days
start oral prednisone 1mg/kg/day or equivalent.
Taper over 4 weeks if symptoms improve. Start
Infliximab 5mg/kg every 2 weeks if symptoms
don’t improve after 3 days on steroid treatment.
Grade 3/4: Severe grade. =7 stools/day over
baseline.
Severe and persistent abdominal pain, fever,
ileus.
Life threatening complications like intestinal
perforation and peritonitis
q Diagnosis: Rule out infectious and other causes
as above.
GI consult and endoscopy in selected cases
q Treatment: Discontinue immunotherapy
I.V. Methyl prednisone 2–4mg/kg/day or
equivalent taper over 4 weeks if symptoms
resolve.
Consider alternative immunosuppressive agent
(Cyclophosphamide or mycophenolate mofetil) if
symptoms don’t improve after 48 h. Monitor for
intestinal perforation.
(Continued)
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TABLE 2 | Continued
S.N. Organ system Manifestations Management
3. Hepatic
q Appears 12–16 weeks after initiation of
treatment with ipilimumab.
q Typically seen after the 3rd dose of checkpoint
inhibitor treatment.
q Mostly asymptomatic elevation of liver enzyme.
Fever, fatigue and jaundice may be seen in some
patients.
q Manifests in <10% patients on anti-CTLA-4
therapy but in ∼20% patients on combination
(anti-CTLA-4 plus anti-PD-1/anti-PD-L1) therapy.
Immune mediated hepatitis
Grade 1: Asymptomatic/mildly symptomatic
AST/ALT of 2.5 × ULN
Total Bilirubin of 1.5 × ULN
q Diagnosis: LFTs.
q Treatment: Continue immunotherapy if
asymptomatic.
Monitor LFTs until resolution
Grade 2: Symptomatic.
AST/ALT of 2.5–5 × ULN
Total Bilirubin of 1.5–3 × ULN
q Diagnosis: Rule out viral, drug induced or
autoimmune causes.
Monitor LFTs daily till resolution followed by
weekly testing.
q Treatment: Withhold immunotherapy.
Resume after toxicity improves to grade 1 or
lower.
Oral Prednisone 1mg/kg/day or equivalent taper
over 4 weeks if symptoms resolve.
Consider alternative immunosuppressive agent
(tacrolimus, cyclophosphamide or
mycophenolate mofetil) if symptoms don’t
improve after 48 h. Infliximab is contraindicated
due to potential hepatotoxicity.
Grade 3/4: Symptoms as above.
AST/ALT of 5 × ULN
Total Bilirubin of 3 × ULN
q Diagnosis: As in grade 2 plus imaging to rule
out malignant etiology. Monitor LFTs daily till
resolution.
q Treatment: Discontinue immunotherapy
I.V. Methyl prednisone 2–4mg/kg/day or
equivalent taper over 4 weeks if symptoms
resolve.
If no improvement after 5–7 days, add
tacrolimus 0.10–0.15mg/kg/day (trough level
5–20 ng/mL). Consider alternative agents
(cyclophosphamide or mycophenolate mofetil), if
no response despite therapeutic levels.
Infliximab is contraindicated.
4. Pulmonary
q Seen after 8–14 weeks of 1st dose of
ipilimumab.
q Asymptomatic appearance of infiltrates on lung
imaging is more common.
q Symptomatic pneumonitis is seen in =1%.
More common with anti-PD-1/anti-PD-L1 than
anti-CTLA-4 therapy
Immune mediated pneumonitis
Grade 1: Asymptomatic, only radiological
changes.
q Diagnosis: Radiological imaging using High
resolution computed tomography (HRCT chest).
Repeat CT before every cycle
q Treatment: Withhold immunotherapy for 2–4
weeks.
Monitor for symptoms every 3 days.
If new symptoms develop, treat as higher grade.
Grade 2: Mild/Moderate new symptoms
limiting instrumental activities of daily living.
q Diagnosis: As above plus microbiological
assessment like sputum examination and
cultures.
q Treatment: withhold immunotherapy. If
symptoms improve to grade 1 within 72 h
resume immunotherapy otherwise discontinue
immunotherapy. Also Discontinue therapy
in recurrent grade 2 pneumonitis.
Monitor for symptoms daily.
Oral prednisone 1mg/kg/day or equivalent.
Taper over 4 weeks if symptoms improve.
Grade 3/4: Severe symptoms limiting self-care
activities of daily living. Hypoxia or Respiratory
failure requiring urgent interventions like
endotracheal intubation or tracheostomy.
q Diagnosis: Rule out infectious and other
pulmonary causes.
Pulmonary consult and bronchoscopy
q Treatment: Discontinue immunotherapy
I.V. Methyl prednisone 2–4mg/kg/day or
equivalent taper over 4 weeks if symptoms
resolve.
Consider prophylactic antibiotics. Consider
alternative immunosuppressive agent
(Cyclophosphamide or Infliximab) if symptoms
don’t improve after 48 h.
(Continued)
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TABLE 2 | Continued
S.N. Organ system Manifestations Management
5. Endocrine
q Generally seen 9 weeks after initiation of
ipilimumab treatment.
q Immune related thyroiditis
Hypothyroidism/Hyperthyroidism:
Fatigue, weakness, asthenia, new onset atrial
fibrillation, constipation/diarrhea, cold/heat
intolerance, dry skin/excessive diaphoresis,
weight gain/weight loss.
q Immune-mediated adrenalitis: Asthenia,
failure to thrive, anorexia, nausea, vomiting, fever,
coma, hypotension, hypoglycemia, eosinophilia.
q Immune -mediated hypophysitis:
Headache, visual field defects, blurring of vision,
impotence, amenorrhea
Immune-mediated endocrinopathies
Grade 1: Asymptomatic or mild symptoms;
clinical or diagnostic observations only;
intervention not indicated
q Diagnosis: Complete blood count,
comprehensive metabolic profile. Consult
endocrine
Thyroiditis: TSH. If TSH is below 0.5 × ULN
or above 2 × ULN or consistently out of normal
range in subsequent cycles consider adding free
T3 and T4.
Adrenalitis: ACTH, Morning serum cortisol-if
abnormal Cosyntropin stimulation test.
Hypophysitis: LH/FSH/Testosterone, Prolactin.
MRI brain with pituitary cuts and visual field
testing if indicated.
q Treatment: Continue immunotherapy.
Monitor for symptoms. If worsens treat as higher
grades.
Treat for hyper or hypothyroidism if indicated
Hypothyroidism is more common with anti-CTLA-4
while hypophysitis and hyperthyroidism is seen
more commonly with anti-PD-1/anti-PD-L1 therapy
Grade 2: Moderate; minimal, local or
noninvasive; intervention indicated; limiting
age-appropriate instrumental ADL
q Diagnosis: As above in grade 1.
q Treatment:
1. Hyper/Hypothyroidism-continue
immunotherapy
2. Adrenalitis: continue immunotherapy.
3. Hypophysitis$: Withhold immunotherapy.
Prednisone 1–2mg/kg/day or equivalent. Taper
over >4 weeks before resuming immunotherapy.
Replace deficient hormone. If patient developed
hypophysitis on ipilimumab, it can be replaced
with pembrolizumab from next cycle.
Grade 3:Severe or medically significant but not
immediately life-threatening; hospitalization or
prolongation of existing hospitalization
indicated; disabling; limiting ADL and self-care
q Diagnosis: As above in grade 1.
q Treatment:
1. Hyper/Hypothyroidism: continue
immunotherapy. Treatment of
hypo/hyperthyroidism as per standard
guidelines.
2. Adrenal insufficiency: withhold
immunotherapy. Prednisone 1–2mg/kg/day or
equivalent. Taper over >4 weeks before
resuming immunotherapy.
3. Hypophysitis: permanently discontinue
immunotherapy. Prednisone 1–2mg/kg/day or
equivalent. Taper over >4 weeks. Few patients
may require hormone replacement therapy for
life.
Grade 4:Life-threatening consequences;
urgent intervention indicated
q Diagnosis: As above in grade 1.
q Treatment:
1. Hyper/Hypothyroidism: continue
immunotherapy. Treatment of
hypo/hyperthyroidism as per standard
guidelines.
2. Adrenal insufficiency: Permanently
discontinue immunotherapy. Prednisone
1–2mg/kg/day or equivalent. Taper over >4
weeks before resuming immunotherapy.
If in adrenal crisis stabilize the patient prior to
endocrine work-up. Rule out sepsis. If in shock,
start with stress dose steroids, antibiotics and iv
fluids.
3. Hypophysitis: permanently discontinue
immunotherapy. Prednisone 1–2mg/kg/day or
equivalent. Taper over >4 weeks. Few patients
may require hormone replacement therapy for
life.
(Continued)
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TABLE 2 | Continued
S.N. Organ system Manifestations Management
6. Renal
q Seen 14–42 weeks after initiation of treatment.
q Rare with both anti-CTLA-4 and
anti-PD-1/anti-PD-L1 therapy
Immune mediated Renal dysfunction
Grade 1: ↑ creatinine above the baseline but
=1.5 ULN
q Diagnosis: Kidney Function Tests, Urine analysis
q Treatment: Continue immunotherapy.
Symptomatic treatment and monitor for fluid
electrolytes balance.
Grade 2 and 3: creatinine 1.5–6 mg/dl ULN q Diagnosis: As in grade 1. Monitor creatinine
every 2–3 days. Consider renal biopsy.
q Treatment: Withhold immunotherapy.
Oral Prednisone 0.5–1mg/kg/day or equivalent,
if no response ↑ to 1–2mg/kg/day and
discontinue immunotherapy permanently. If
elevation persists =7 days treat as grade 4.
Grade 4: creatinine > 6 mg/dl ULN q Diagnosis: As in grade 1. Monitor creatinine
every day. Consider renal biopsy. Consult
nephrology
Treatment: Withhold immunotherapy.
Oral Prednisone 1–2mg/kg/day. Taper at least
over 4 weeks.
7. Neurologic
Headache, fever, stiffness, memory problem,
confusion, drowsiness, hallucinations, seizures,
peripheral neuropathy
Immune-mediated neurological adverse
reactions
Grade 1: Asymptomatic or mildly symptomatic
q Diagnosis: Clinical examination
q Treatment: Continue immunotherapy.
Monitor for progression of disease.
Rare with both anti-CTLA-4 and
anti-PD-1/anti-PD-L1 therapy
Grade 2: New onset moderate symptoms
limiting instrumental activities of daily living.
q Diagnosis: Monitor for progression of disease.
q Treatment: Withhold immunotherapy.
Consider consulting neurology. Oral prednisone
0.5–1mg/kg/day or equivalent. If no response
treat as grade 3 and 4.
Grade 3 and 4: New onset severe symptoms
affecting self-care activities of daily living. Life
threatening.
q Diagnosis: MRI brain, lumbar puncture, nerve
conduction velocity, electromyography, skin,
nerve or muscle biopsy as clinically indicated.
q Treatment: Permanently discontinue
immunotherapy. Consult neurology.
Prednisone 1–2mg/kg/day or equivalent. Taper
over at least 4 weeks. If worsens or atypical
presentation consider other immunosuppressive
agents.
ADL, activities of daily living; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; CTLA-4, cytotoxic T-lymphocyte antigen-4; FSH, follicular
stimulating hormone; KFT, kidney function test; LFT, liver function tests; LH, luteinizing hormone; MRI, magnetic resonance imaging; PD-1, programmed cell death; PD-L1, programmed
cell death ligand-1; TSH, thyroid stimulating hormone; ULN, upper limit of normal.
For References see text.
*Common Terminating Criteria for Adverse Events Grading.
#Patients receiving prednisone =20 mg/day or equivalent doses for at least 4 weeks are candidates for pneumocystis jirovecii prophylaxis as per National Comprehensive Cancer
Network NCCN guidelines.
**Treatment with checkpoint inhibitors is permanently discontinued in grade 2 toxicity if it persists beyond 6 weeks. However PD-1 inhibitors can be continued with hormone replacement
in endocrinopathies.
@Nivolumab is permanently discontinued if prednisone can’t be tapered to <7.5 mg/day or equivalent without recurrence of symptoms and ipilimumab is discontinued if prednisone
can’t be tapered below 10mg/kg/day or equivalent dose.
$Prednisone dose in hypophysitis is controversial. New data suggests that physiological dose is as effective as higher doses advocated previously. See text.
budesonide for prophylaxis against colitis has not been proven
and is not recommended (Weber et al., 2009).
Hepatic
Hepatotoxicity can be caused by both anti-CTLA-4 and
anti-PD-1/anti-PD-L1 antibodies. Hepatotoxicity occurs in 2–9%
of patients (Weber, 2009; Ibrahim et al., 2011; Tarhini et al.,
2012; Borghaei et al., 2015; Calabro et al., 2015; Garon et al.,
2015; Rizvi et al., 2015; Robert et al., 2015b; Kindler et al., 2016;
Nanda et al., 2016; Rosenberg et al., 2016; Seiwert et al., 2016).
Liver function should be tested at baseline and prior to each
cycle of immunotherapy. The patients should also be monitored
regularly during the post-treatment period. An asymptomatic
elevation of hepatic transaminases and hyperbilirubinemia is
common, and concomitant fever can also occur (Weber,
2012). Liver biopsy is reserved for unclear cases and reveals
prominent sinusoidal histiocytic infiltrates and central vein
damage with endotheliitis suggestive of ipilimumab-associated
hepatitis (Johncilla et al., 2015). Grade 2 reactions require
interruption of cancer treatment, with daily or alternate-day
monitoring of liver enzymes until they decrease, and then
subsequent weekly assessments (Table 2). Grade 3 or greater
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irAEs involve AST/ALT levels >5 times upper limit of normal
(ULN) or bilirubin>3 times ULN. Severe hepatotoxicity requires
high-dose intravenous glucocorticoids for 24–48 h followed
by a slow taper for the next 30 days. The glucocorticoids
should be switched to mycophenolate 500mg every 12 h if the
liver enzymes are still elevated after 48 h of treatment2,3,4,5.
The use of infliximab is contraindicated due its potential
hepatotoxicity. The differential diagnoses of immunotherapy-
induced liver damage include metastasis to the liver, viral
hepatitis and other drug toxicity meriting extensive analysis.
Hepatitis persisting for longer periods requires prolonged or
repeated glucocorticoids tapering (≥4 weeks) and/or additional
immunosuppression2,3,4,5.
Endocrine
Endocrinopathies can occur secondary to inflammation of the
pituitary, thyroid and adrenal glands or may be related to
development of type-1 diabetes mellitus. Clinical presentation
is confounded by nonspecific symptoms such as behavioral
changes, nausea, headache, fatigue and visual complaints
(Corsello et al., 2013). Hypophysitis and hypothyroidism are the
most common endocrinopathies seen in up to 10% of patients
treated with anti-CTLA-4 and anti-PD-1/anti-PD-L1 antibodies
(Weber, 2009; Hodi et al., 2010; Wolchok et al., 2010; Ibrahim
et al., 2011; Topalian et al., 2012, 2014; Tarhini et al., 2012; Ribas
et al., 2013b; Borghaei et al., 2015; Calabro et al., 2015; Garon
et al., 2015; Larkin et al., 2015; Postow et al., 2015; Rizvi et al.,
2015; Robert et al., 2015a,b; Ferris et al., 2016; Kindler et al., 2016;
Nanda et al., 2016; Seiwert et al., 2016; Rosenberg et al., 2016)1.
Hypophysitis with pituitary dysfunction requires testing
for thyroid stimulating hormone (TSH), serum cortisol,
adrenocorticotropic hormone (ACTH), growth hormone (GH),
prolactin, luteinizing hormone (LH), and follicular stimulating
hormone (FSH) in women or testosterone levels in men.
Diagnosis is based on clinical symptoms with radiographic
abnormalities (pituitary enlargement with enhancement) and
biochemical test results (low tropic hormones)2,3,4,5. The role
of high dose glucocorticoids (1 mg/kg prednisone daily) is
controversial in cases with suspected hypophysitis. The use of
physiological replacement doses has been suggested, and high
doses should be reserved for patients with symptoms related
to mass effects such as severe headaches or visual disturbances
(Albarel et al., 2015). A recent study reported that TSH and FSH
normalized after a follow-up period of 33 months. However,
ACTH remained low, with persistent pituitary abnormalities on
MRI irrespective of glucocorticoid dose (Albarel et al., 2015; Min
et al., 2015).
The routinemonitoring of thyroid function is indicated before
each dose of ipilimumab. Hypothyroidism is more common
than hyperthyroidism. It is important to distinguish primary
hypothyroidism (low free T4 with high TSH) from secondary
disease (low free T4 with low TSH) caused by hypophysitis. The
treatment of hypo and hyperthyroidism should be consistent
with standard guidelines (Table 2)2,3,4,5. Immunotherapy can be
continued with hormone replacement.
Hypophysitis2,3,4,5 with clinically significant adrenal
insufficiency (hypotension, dehydration, and dyselectrolytemia)
is equivalent to adrenal crisis and is a medical
emergency that mandates hospitalization, evaluation by an
endocrinologist and treatment with methylprednisolone.
It is important to distinguish this condition from
sepsis, and prompt testing with cultures is mandatory
(Table 2).
Pulmonary
Grade 3 or higher pneumonitis has been reported in 5–7% of
NSCLC patients treated with nivolumab and pembrolizumab
(Langer, 2015; Abdel-Rahman and Fouad, 2016). The incidence
of symptomatic pneumonitis is only 1% with ipilimumab
(Barjaktarevic et al., 2013). The risk increased in patients
with prior thoracic radiation. There have been reported
granulomatous reactions similar to sarcoidosis (Berthod et al.,
2012). The presence of infiltrates on chest radiographs or
CT imaging is more common and resolves rapidly after
withholding the drug. Pneumonitis should be excluded by CT
imaging in any patient with cough, shortness of breath, and
fever2,3,4,5. A bronchoscopy may reveal diffuse lymphocytic
infiltration and should be performed in moderate to severe
cases to exclude infections. Severe cases should be treated with
glucocorticoids using 2 mg/kg intravenous methyl prednisolone.
Immunotherapy should be permanently discontinued in cases
with recurrent grade 2–4 irAEs (Table 2)2,3,4,5.
Rare Events
Ocular
Common ocular manifestations include episcleritis,
conjunctivitis and uveitis. The incidence of these events is
higher with ipilimumab but remains less than 1% (Huillard et al.,
2014; Abu Samra et al., 2016). The patient should be referred to
an ophthalmologist and treatment with topical glucocorticoids is
required in most cases. The use of oral glucocorticoid therapy is
reserved for severe events.
Renal
ICIs can cause acute kidney injury that presents similar to other
drug-induced tubulointerstitial nephritis. The median duration
for the appearance of the kidney injury is 13 weeks (Cortazar
et al., 2016). In addition to nephritis, granulomatous lesions and
thrombotic microangiopathy can also be seen on renal biopsy.
A previous study demonstrated that renal function partially
improved after glucocorticoid treatment, and that one-third of
patients required dialysis (Cortazar et al., 2016). Grade 2 or
higher toxicity is treated with glucocorticoids (Table 2). The
immunotherapy should be withheld for Grade 2–3 events and
permanently discontinued for Grade 4 events or resistant Grade
2–3 irAEs2,3,4,5.
Pancreatic
Routinemonitoring of amylase/lipase in otherwise asymptomatic
individuals is not recommended. Asymptomatic elevation does
not require treatment. The significance of elevated amylase and
lipase in a large number of patients remains unclear (Ribas et al.,
2013b; Postow et al., 2015; Herbst et al., 2016).
Neurological
The reported neurologic complications of immunotherapies
include posterior reversible encephalopathy syndrome (Maur
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et al., 2012), Guillain-Barre Syndrome (Wilgenhof and Neyns,
2011), myasthenia gravis (Liao et al., 2014), transverse myelitis
(Liao et al., 2014), and neuropathy (de Maleissye et al., 2016).
Serious cases should be treated with glucocorticoids and a
neurologist should be consulted for additional therapies such as
intravenous immunoglobulin and plasmapheresis. (for detailed
management see Table 2)
Hematological
Autoimmune anemia (Kong et al., 2016), neutropenia (Akhtari
et al., 2009), thrombocytopenia (Ahmad et al., 2012), and
acquired hemophilia A have been reported (Delyon et al., 2011).
Symptom management is similar to other irAEs and involves
the use of glucocorticoids and alternative immunosuppression in
refractory cases.
Combination Therapy
The distinct mechanisms of action of anti-CTLA-4 and anti-
PD-1/anti-PD-L1 antibodies have led to trials examining
combination therapies in a variety ofmalignancies. The incidence
of severe adverse events due to the combination of ipilimumab
and nivolumab is reported to be 55%, which is significantly
higher than either agent individually and leads to discontinuation
of treatment in one-third of patients (Larkin et al., 2015). The
toxicity profile of ipilimumab varies with the chemotherapy
agent used in combination (Weber J. et al., 2013). The
combination with dacarbazine is more hepatotoxic (Robert et al.,
2011), and carboplatin and taxanes treatment leads to more
cutaneous manifestations (Arriola et al., 2016). There are more
nephrotoxic and hepatotoxic events observed when combined
with vemurafenib (Ribas et al., 2013a). The combination of
ipilimumab (dose 10 mg/kg) with granulocyte-macrophage
colony-stimulating factor showed fewer gastrointestinal and
pulmonary irAEs than ipilimumab alone (45 vs. 58%)(Hodi et al.,
2014). However, the efficacy of this combination is not clear
at the FDA-approved dose of 3 mg/kg and requires further
confirmation.
Autoimmune Conditions
The safety of ICIs in patients with preexisting autoimmune
diseases is not clear, and there is a theoretical concern
regarding the exacerbation of preexisting conditions. There have
been anecdotal reports of patients with anti-muscle antibodies
developing rhabdomyolysis with polymyositis (Bilen et al.,
2016), and neurotoxicity has been described in patients with
anti-neuronal antibodies (Williams et al., 2016). Ipilimumab
treatment led to the exacerbation of previously diagnosed
autoimmune conditions in 27% of patients within 6 weeks
of treatment, and these conditions were easily managed with
steroids (Johnson et al., 2015). Clinicians should engage
patients in discussions for trial of these agents due to
the significant benefit of these antibodies in life-threatening
malignancies. The development of new autoimmune syndromes
(30% sicca syndromes, 70% inflammatory arthritis and 40%
ANA positivity) have also been reported in patients without
any prior history of rheumatic conditions (Cappelli et al.,
2017).
CONCLUSION
ICIs targeting CTLA-4 and PD-1/PDL-1 have dramatically
changed the outcomes of patients with many advanced-stage
malignancies. However, their introduction is associated with
unique irAEs that are mostly transient and mild but can
occasionally be fatal. Rapid identification and appropriate
treatment can improve outcomes without compromising the
efficacy of these agents. In the absence of prospective data, these
patients should be managed as per established guidelines based
upon pooled clinical experience. Additional data on toxicities will
enable us to utilize the full therapeutic potential of these novel
drugs.
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